Pricing Covid-19 vaccines too high could backfire on big pharmaceutical companies. . I don’t want to single out Moderna here. It doesn’t have a single successful commercial drug, nor any other Phase 3 candidates; its need to make money off this vaccine is arguably acute. Larger drug companies are different. Yet Pfizer NSE 2.30% Inc.’s CEO recently said that calls for companies not to consider making a profit on their Covid-19 vaccines were “fanatic and radical.” (AstraZeneca NSE 1.51% PLC and Johnson & Johnson have promised a not-for-profit effort on their Covid-19 vaccines,
Nuestra amiga favorita de los foros de farma devuelve "datos prometedores" en fase 1 (a mi, la verdad, a estas alturas de la película me cuesta creérmela)...
Novavax’s coronavirus vaccine generates promising immune response in early trial, data shows
Sorrento Therapeutics (SRNE +23.6%) is adding to its recent breakout on almost double normal volume. Shares have jumped 159% since Wednesday, July 24, when it announced that it planned to acquire COVID-19 therapy developer SmartPharm Therapeutics. The following Monday, July 29, it announced that it in-licensed rights to a rapid test that detects the presence of the SARS-CoV-2 virus in saliva in as little as 30 minutes.
On Friday, May 15, shares rocketed 158% after the company announced a "cure" for COVID-19. Shares quickly retraced on questions about the veracity of its claim, bottoming at $3.82 on June 4. Investors appeared to have brushed off such concerns since shares are up five-fold since then. Chairman, CEO and President Henry Li, Ph.D. is, no doubt, pleased with the share appreciation. Last week, the board authorized a 10-year performance award for him based solely on the market cap of the company. He will earn options to purchase up to ~24.9M shares at $17.30 representing a 10% stake in the company if fully exercised. The award vests in 10 equal tranches starting with ~2.5M options if the company's market cap reaches $5B. The 10th and last tranche vests if the company's value hits $35B. Assuming full vestment and no further equity offerings, his total award will be potentially worth ~$3.3B.
